Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 7 | Journal of Ovarian Research

Fig. 7

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 7

hTC, − 279/+ 5, Ran, and Brms1 Promoters. hTC displayed significantly higher expression levels than all other cancer-specific promoters in all four cell lines. Brms1 displayed the second highest expression levels in all cell lines but Ovcar3, where it showed very similar expression to the − 279/+ 5 promoter. Each column represents n = 3, and all data were analyzed with 1-way ANOVA and Tukey’s post-test. *** indicates p < 0.001, while ** indicates p < 0.01

Back to article page